Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Total Non-Current Liabilities (2020 - 2025)

Mirum Pharmaceuticals has reported Total Non-Current Liabilities over the past 6 years, most recently at $523.1 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $523.1 million for Q4 2025, up 18.19% from a year ago — trailing twelve months through Dec 2025 was $523.1 million (up 18.19% YoY), and the annual figure for FY2025 was $523.1 million, up 18.19%.
  • Total Non-Current Liabilities for Q4 2025 was $523.1 million at Mirum Pharmaceuticals, up from $477.1 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for MIRM hit a ceiling of $523.1 million in Q4 2025 and a floor of $37.5 million in Q1 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $373.3 million (2023), compared with a mean of $299.2 million.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 716.57% in 2021 and later rose 7.27% in 2025.
  • Mirum Pharmaceuticals' Total Non-Current Liabilities stood at $172.4 million in 2021, then increased by 21.65% to $209.8 million in 2022, then skyrocketed by 87.87% to $394.1 million in 2023, then rose by 12.31% to $442.6 million in 2024, then increased by 18.19% to $523.1 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $523.1 million (Q4 2025), $477.1 million (Q3 2025), and $461.6 million (Q2 2025) per Business Quant data.